StreetInsider.com News Articles

Form 424B5 Alector, Inc.

Fri, 16 Oct 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20261016/27198477.html

Form 8-K Alector, Inc. For: Oct 15

Fri, 16 Oct 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20261016/27198442.html

Alector stock surges 13% on premium-priced equity offering

Fri, 16 Oct 2026 09:46:56 -0400

Investing.com -- Alector shares surged about 13% in premarket trading Friday following the company’s announcement of a $75 million stock offering priced at a premium to the previous day’s close.

The South San Francisco-based biotechnology company priced an underwritten offering of 36.6 million shares of common stock at $2.05 per share, representing a premium of approximately 7.3% over the October 15, 2026 closing price. The gross proceeds are expected to reach $75.03 million before deducting underwriting discounts, commissions, and other offering expenses.

The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. The

Alector stock surges 13% on premium-priced equity offering

Fri, 16 Oct 2026 09:46:56 -0400

Investing.com -- Alector shares surged about 13% in premarket trading Friday following the company’s announcement of a $75 million stock offering priced at a premium to the previous day’s close.

The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. The

Form FWP Alector, Inc. Filed by: Alector, Inc.

Fri, 16 Oct 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20261016/27195733.html

Form 4 Alector, Inc. For: Oct 14 Filed by: Berkley Neil Lindsay

Thu, 15 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261015/27193367.html

Form 4 Alector, Inc. For: Oct 13 Filed by: Wong-Sarad Grace

Thu, 15 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261015/27193377.html

Form 4 Alector, Inc. For: Oct 13 Filed by: Rosenthal Arnon

Thu, 15 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261015/27193381.html

Alector Inc. (ALEC) PT Raised to $8 at H.C. Wainwright

Thu, 15 Oct 2026 07:12:06 -0400

(Updated - October 15, 2026 7:12 AM EDT)

H.C. Wainwright analyst Andrew Fein raised the price target on Alector Inc. (NASDAQ: ALEC) to $8.00 (from $5.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Alector’s R&D Day showcased a pipeline built on its Alector Brain Carrier (ABC), a transferrin receptor (TfR)-based blood-brain barrier (BBB) shuttle. We think the company has done more than pivot from standard antibodies against novel microglial targets (TREM2, progranulin) to validated targets. With ABC, we believe Alector has become a platform company, where one shuttle can be paired with antibody, enzyme or siRNA cargo, allowing Alector to

Alector Inc. (ALEC) PT Raised to $8 at H.C. Wainwright

Thu, 15 Oct 2026 07:12:06 -0400

(Updated - October 15, 2026 7:12 AM EDT)

H.C. Wainwright analyst Andrew Fein raised the price target on Alector Inc. (NASDAQ: ALEC) to $8.00 (from $5.00) while maintaining a Buy rating.

Form 8-K Alector, Inc. For: Oct 13

Wed, 14 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27184685.html

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

Wed, 07 Oct 2026 16:05:00 -0400

Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's wholly owned ABC blood-brain barrier platform and programs in its ABC-enabled pipeline.

Details of the webinar are as follows:

Alector Pipeline Webinar: Advancing Next Generation

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

Wed, 07 Oct 2026 16:05:00 -0400

Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's wholly owned ABC blood-brain barrier platform and programs in its ABC-enabled pipeline.

Details of the webinar are as follows:

Alector Pipeline Webinar: Advancing Next Generation

Alector Inc. (ALEC) PT Raised to $3 at Morgan Stanley

Tue, 06 Oct 2026 06:15:52 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Alector Inc. (NASDAQ: ALEC) to $3.00 (from $2.00) while maintaining a Underweight rating.
The analyst comments "We now ascribe credit for AL050 ($100M in milestones booked in 4Q) and extend the model through 2037, adding ~$50M in milestones from FDA approval and ~$5M in royalty revenue (~$1.17B in net milestones pending). Finally, we lower R&D in 2H26, offset by increasing R&D spend in FY27. Our bull case increases to $12 (from $7) reflecting the addition of risk adj. revenues for AL050, whereas our base case and bear case assume net cash/sh,

Alector Inc. (ALEC) PT Raised to $3 at Morgan Stanley

Tue, 06 Oct 2026 06:15:52 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Alector Inc. (NASDAQ: ALEC) to $3.00 (from $2.00) while maintaining a Underweight rating.
The analyst comments "We now ascribe credit for AL050 ($100M in milestones booked in 4Q) and extend the model through 2037, adding ~$50M in milestones from FDA approval and ~$5M in royalty revenue (~$1.17B in net milestones pending). Finally, we lower R&D in 2H26, offset by increasing R&D spend in FY27. Our bull case increases to $12 (from $7) reflecting the addition of risk adj. revenues for AL050, whereas our base case and bear case assume net cash/sh,

Mizuho Reiterates Neutral Rating on Alector Inc. (ALEC)

Tue, 06 Oct 2026 05:16:03 -0400

Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $1.50 price target on Alector Inc. (NASDAQ: ALEC)
The analyst comments "Yesterday, ALEC announced a global partnership with Roche's (RHHBY, NC) subsidiary, Genentech, for AL050, a preclinical blood-brain-barrier/BBB technology-enabled GCase enzyme replacement therapy/ERT for Parkinson's disease/PD. Overall, we viewed the news positively, with the deal providing ALEC both large pharma validation and cash, but also a chance for "Alector v2.0" (i.e. post-its prior late-stage clinical disappointments) to get off the ground running. Overall, we remain highly enthusiastic about the promise of BBB-enabled drug candidates; that said, regarding ALEC, amidst a very competitive

Biotech Brainiacs and Breakthroughs

Mon, 05 Oct 2026 09:51:31 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ: ALEC) and NeOnc Technologies (NASDAQ: NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ: PCVX) delivers a potentially market-shifting Phase 3 vaccine readout.

Alector Lands A $1.27 Billion Genentech Deal

Alector (NASDAQ: ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential

Biotech Brainiacs and Breakthroughs

Mon, 05 Oct 2026 09:51:31 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ: ALEC) and NeOnc Technologies (NASDAQ: NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ: PCVX) delivers a potentially market-shifting Phase 3 vaccine readout.

Alector Lands A $1.27 Billion Genentech Deal

Alector (NASDAQ: ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential

Biotech Brainiacs and Breakthroughs

Mon, 05 Oct 2026 09:51:31 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ: ALEC) and NeOnc Technologies (NASDAQ: NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ: PCVX) delivers a potentially market-shifting Phase 3 vaccine readout.

Alector Lands A $1.27 Billion Genentech Deal

Alector (NASDAQ: ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential

Biotech Brainiacs and Breakthroughs

Mon, 05 Oct 2026 09:51:31 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ: ALEC) and NeOnc Technologies (NASDAQ: NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ: PCVX) delivers a potentially market-shifting Phase 3 vaccine readout.

Alector Lands A $1.27 Billion Genentech Deal

Alector (NASDAQ: ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential

Biotech Brainiacs and Breakthroughs

Mon, 05 Oct 2026 09:51:31 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ: ALEC) and NeOnc Technologies (NASDAQ: NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ: PCVX) delivers a potentially market-shifting Phase 3 vaccine readout.

Alector Lands A $1.27 Billion Genentech Deal

Alector (NASDAQ: ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential

Biotech Brainiacs and Breakthroughs

Mon, 05 Oct 2026 09:51:31 -0400

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ: ALEC) and NeOnc Technologies (NASDAQ: NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ: PCVX) delivers a potentially market-shifting Phase 3 vaccine readout.

Alector Lands A $1.27 Billion Genentech Deal

Alector (NASDAQ: ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential

Alector licenses Parkinson's therapy to Genentech for up to $1.27B

Mon, 05 Oct 2026 07:00:15 -0400

Alector, Inc. (Nasdaq: ALEC) has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize AL050, Alector's investigational brain-penetrant glucocerebrosidase (GCase) enzyme replacement therapy, according to a press release.

Under the terms of the agreement, Alector will receive an upfront payment of $100 million, with potential additional payments of up to $1.17 billion tied to development, regulatory, and commercial milestones. Alector is also eligible for tiered royalties on net sales. Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications.

AL050 is designed to address GCase

Form 8-K Alector, Inc. For: Sep 30

Mon, 05 Oct 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20261005/27145439.html

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Mon, 05 Oct 2026 07:00:00 -0400

Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector’s proprietary blood-brain barrier delivery platform

Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement